CN101798279B - 铁催化的吡咯及吡咯并环类化合物的制备方法 - Google Patents
铁催化的吡咯及吡咯并环类化合物的制备方法 Download PDFInfo
- Publication number
- CN101798279B CN101798279B CN201010130160XA CN201010130160A CN101798279B CN 101798279 B CN101798279 B CN 101798279B CN 201010130160X A CN201010130160X A CN 201010130160XA CN 201010130160 A CN201010130160 A CN 201010130160A CN 101798279 B CN101798279 B CN 101798279B
- Authority
- CN
- China
- Prior art keywords
- pyrrole
- compounds
- catalyzed
- pyrrolocyclic
- nmr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title abstract description 37
- 238000000034 method Methods 0.000 title abstract description 10
- -1 pyrrole cyclic compounds Chemical class 0.000 title abstract description 7
- 150000003233 pyrroles Chemical class 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 238000006243 chemical reaction Methods 0.000 claims description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 claims description 6
- 239000012074 organic phase Substances 0.000 claims description 5
- IBXNCJKFFQIKKY-UHFFFAOYSA-N 1-pentyne Chemical compound CCCC#C IBXNCJKFFQIKKY-UHFFFAOYSA-N 0.000 claims description 4
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 claims description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- 150000002576 ketones Chemical class 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- 238000010898 silica gel chromatography Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 3
- DYRDKSSFIWVSNM-UHFFFAOYSA-N acetoacetanilide Chemical compound CC(=O)CC(=O)NC1=CC=CC=C1 DYRDKSSFIWVSNM-UHFFFAOYSA-N 0.000 claims description 3
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 238000000967 suction filtration Methods 0.000 claims description 3
- 229950001902 dimevamide Drugs 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims 2
- 238000004821 distillation Methods 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 2
- 238000003760 magnetic stirring Methods 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 238000000605 extraction Methods 0.000 claims 1
- 239000008247 solid mixture Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 11
- 150000003839 salts Chemical class 0.000 abstract description 9
- 239000003054 catalyst Substances 0.000 abstract description 7
- 238000007363 ring formation reaction Methods 0.000 abstract description 6
- 230000003197 catalytic effect Effects 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 5
- 230000007613 environmental effect Effects 0.000 abstract description 4
- 229910052737 gold Inorganic materials 0.000 abstract description 4
- 229910052763 palladium Inorganic materials 0.000 abstract description 4
- 229910052709 silver Inorganic materials 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 229910052802 copper Inorganic materials 0.000 abstract description 3
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 230000002194 synthesizing effect Effects 0.000 abstract description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 17
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- ASVQKRFMRKDHTD-UHFFFAOYSA-N pent-4-yn-2-one Chemical compound CC(=O)CC#C ASVQKRFMRKDHTD-UHFFFAOYSA-N 0.000 description 11
- 239000002904 solvent Substances 0.000 description 8
- 238000010183 spectrum analysis Methods 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 150000003141 primary amines Chemical class 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- JBIJLHTVPXGSAM-UHFFFAOYSA-N 2-naphthylamine Chemical compound C1=CC=CC2=CC(N)=CC=C21 JBIJLHTVPXGSAM-UHFFFAOYSA-N 0.000 description 1
- 101710134784 Agnoprotein Proteins 0.000 description 1
- AGUGDFCSNXDRKY-UHFFFAOYSA-N CC(C(CC#C)C(Nc1ccccc1)=O)=O Chemical compound CC(C(CC#C)C(Nc1ccccc1)=O)=O AGUGDFCSNXDRKY-UHFFFAOYSA-N 0.000 description 1
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 1
- 238000003445 Hantzsch reaction Methods 0.000 description 1
- 238000006945 Knorr synthesis reaction Methods 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 238000006086 Paal-Knorr synthesis reaction Methods 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 150000003998 acyclic ketones Chemical class 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 238000005447 aza-Wittig reaction Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 150000003997 cyclic ketones Chemical class 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000006452 multicomponent reaction Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate group Chemical group [N+](=O)([O-])[O-] NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000006578 reductive coupling reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- QRUBYZBWAOOHSV-UHFFFAOYSA-M silver trifluoromethanesulfonate Chemical compound [Ag+].[O-]S(=O)(=O)C(F)(F)F QRUBYZBWAOOHSV-UHFFFAOYSA-M 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003457 sulfones Chemical group 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 150000003852 triazoles Chemical group 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Landscapes
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyrrole Compounds (AREA)
Abstract
本发明属于有机合成化学技术领域,具体涉及一种铁催化的吡咯及吡咯并环类化合物的制备方法。本发明提供一种三价铁盐FeX3催化的吡咯及稠吡咯衍生物的制备方法。包括ω,γ-炔酮化合物的合成、成环反应等。发展了一种三价铁盐FeX3催化的ω,γ-炔酮化合物与伯胺化合物的环合反应,可以高效、高收率地制得高纯度的吡咯及吡咯并环衍生物。与现有的Pd、Au、Ag、Cu催化剂相比较,三价铁盐FeX3具有环境友好、价格低廉的优点,本发明具有操作简单,原料和试剂易得,条件温和,催化体系绿色环保,产物易分离纯化,适用于合成各种取代的吡咯及吡咯并环类化合物,特别适用于大规模的工业生产。
Description
技术领域
本发明属于有机合成化学技术领域,本发明涉及一种铁催化的吡咯及吡咯并环类化合物的制备方法。
背景技术
吡咯是一类重要的杂环化合物,不仅是许多生物活性天然产物、药物以及有机导电材料等的关键结构单元,而且还是多用途的有机合成子,所以发展吡咯环的合成方法一直是有机合成化学的重要研究课题之一(Comprehensive Heterocyclic Chemistry III 2008,3,pp 45-268.;Nat.Prod.Rep.,2006,23,517-531.;ARKIVOC2007,10,121-141.)。到目前为止已经发展的方法包括:Knorr合成、Hantzsch反应、Paal-Knorr缩合反应、还原偶联反应、氮杂Wittig反应、多组分偶联方法学以及其它的多步操作反应等。其中,4-戊炔酮与伯胺的[4C+1N]型环合反应是一条简便的合成多取代的吡咯及吡咯并环类化合物的方法,然而仅有几种Lewis酸如NaAuCl4、Na2PdCl4、AgOTf、AgNO3、CuI被用于催化该环合反应,其缺点是Pd、Au、Ag属于贵金属,而且对环境有污染,缺乏实用价值(J.Org.Chem.2006,71,4525-4529.;Adv.Synth.Catal.2001,343,443-446.)。此外,这些公开的催化体系还有一些缺陷,例如:底物范围窄,反应时间长,反应步骤复杂,产物产率低等。
近年来,铁催化的有机化学反应成为了当前有机化学研究的热点方向之一,多种铁催化的化学反应已经被报道,比如氧化反应、还原反应、碳-碳偶联反应、碳-杂原子偶联反应、傅-克反应、多组分反应等(Iron Catalysis in Organic Chemistry.Plietker B.Ed.,Wiley-VCH,2008,Weinheim)。随着全球生态环境的急剧恶化,如何实现可持续发展已成为人类面临的重大问题,以从源头上消除污染、节省资源为核心的绿色化学研究已经成为解决日益严峻的生态环境问题的强有力手段(Energy Environ.Sci.2009,2,1038-1049.)。铁作为催化剂具有环境友好、价格低廉等优点,这些优点使其特别适合作为化学工业生产的催化剂。到目前为止,铁催化的4-戊炔酮化与伯胺化合物合成吡咯及吡咯并环类化合物的反应还未见文献报道。
发明内容
本发明的目的是针对已有的由4-戊炔酮与伯胺反应制备吡咯及吡咯并环类化合物方法的缺点,例如,使用价格昂贵或对环境有污染的Pd、Au、Ag、Cu金属催化体系,提供一种价格低廉、环境友好的铁盐催化体系,更加简便、高效地合成多取代吡咯及吡咯并环类化合物。
本发明提供一种三价铁盐FeX3催化的吡咯及稠吡咯衍生物的制备方法。发展了三价铁盐FeX3催化的4-戊炔酮与伯胺的环合反应,制备一系列多取代的吡咯及吡咯并环衍生物。
其反应方程式如下:
包括将一种4-戊炔酮化合物1与伯胺R5NH2在三价铁盐FeX3催化作用下在非水溶剂中反应得到取代的吡咯及吡咯并环化合物2,其中,R1为氢原子、烷基、芳基、杂芳基、卤原子,R2为氢原子、烷基、芳基、杂芳基、烷氨基、芳氨基、烷氧基、芳氧基、砜基、硝基、卤原子、三氮唑,R3为氢原子、烷基、芳基、氨基、烷胺基,R4为氢原子、烷基、芳基、杂芳基、卤原子,R5为氢原子、烷基、芳基、杂芳基、烷氧基、磺酰、磺酰氨基、亚胺基、羰基、酯基。用本发明方法可以高效地得到高纯度的吡咯及吡咯并环衍生物。
本发明的制备方法包括4-戊炔酮化合物的合成、成环反应等。
具体过程可表示如下:
(1)非环状的或者环状的酮与炔丙基溴类化合物在碱和一定溶剂中反应,生成4-戊炔酮化合物1。
其用量为:酮与炔丙基溴与碱的摩尔比为1∶1-2∶2-3,以大致相等的摩尔数为最好,碱的量为2倍量的摩尔数为最好。碱为K2CO3,NaH。溶剂为极性溶剂,例如N,N-二甲基甲酰胺(DMF)、1,4-二氧六环。反应温度为室温,反应时间一般为12小时。
(2)在一定量的催化剂三价铁盐FeX3存在下,在一定的反应温度和溶剂中,4-戊炔酮1与伯胺R5NH2反应,生成多取代的吡咯及吡咯并环衍生物2。
相对于4-戊炔酮化合物1,催化剂三价铁盐FeX3的用量为0.1mol%-30mol%,用量越大反应越快,综合考虑以10mol%为最好。反应温度为50-130℃,以100℃为最佳。溶剂可以选择甲苯、苯、1,4-二氧六环、乙腈、二甲基甲酰胺、乙醇,以高沸点、非极性的苯类溶剂如甲苯、苯为最好。
与已经公开的Pd、Au、Ag、Cu催化剂相比较,三价铁盐FeX3具有环境友好、价格低廉的优点,本发明具有操作简单,原料和试剂易得,条件温和,催化体系绿色环保,产物易分离纯化,适用于合成各种取代的吡咯及吡咯并环类化合物,特别适用于大规模的工业生产,可以高效、高收率地制得高纯度的吡咯及吡咯并环衍生物。
附图说明
图1为制备铁催化的吡咯及吡咯并环类化合物的反应方程式;
图2为吡咯2a的1H-NMR的核磁共振谱;
图3为吡咯2a的13C-NMR的核磁共振谱;
图4为吡咯2e的1H-NMR的核磁共振谱;
图5为吡咯2e的13C-NMR的核磁共振谱。
具体实施方式
下面的实施例将有助于说明本发明,但是不局限其范围。
实施例1
1)4-戊炔酮化合物1a的制备
向带有磁力搅拌装置的50mL圆底烧瓶中加入无水N,N-二甲基甲酰胺(DMF)(15mL)、N-乙酰乙酰苯胺(1.77g,10mmol)和无水碳酸钾(1.66g,12mmol),在室温20℃、搅拌状态下,缓慢滴加3-溴丙炔(1.43g,12mmol),滴加速率以1滴/2秒为宜。持续搅拌12小时,得淡黄色反应液。将反应液倾入饱和氯化钠水溶液中(20mL),用二氯甲烷(3×15mL)萃取,合并有机相,然后用水(3×10mL)反洗有机相,经过无水氯化钙干燥、抽虑、减压蒸馏等步骤得到粘稠的固体,经过硅胶柱层析(洗脱液为V石油醚∶V乙酸乙酯=10∶3)得到白色固体1.25g,产物的结构经过NMR、MS证实为4-戊炔酮化合物1a,收率为58%。
2)吡咯衍生物2a的制备
向带有磁力搅拌装置的25mL圆底烧瓶中加入二甲苯(2mL)、4-戊炔酮化合物1a(0.22g,1mmol)、4-氯苯胺(0.13g,1mmol)和无水三氯化铁(0.016g,0.1mmol),搅拌均匀后,将其放入80℃油浴中继续搅拌。TLC检测底物消失,反应结束。将反应液倾入饱和氯化钠水溶液(5mL)中,用二氯甲烷(3×5mL)萃取,合并有机相,无水氯化钙干燥、抽虑,然后减压蒸馏除去有机溶剂,得到固体混合物,最后经过硅胶柱层析(洗脱液为V石油 醚∶V乙酸乙酯=10∶3)得到淡黄色固体0.27g,经过NMR、MS证实为吡咯衍生物2a,其收率以2-乙酰基-N-苯基-4-炔戊酰胺为基础为83%。
谱图解析数据2a:
1H NMR(500MHz,CDCl3)δ=2.02(s,3H),2.35(s,3H),6.20(s,1H),7.08-7.11(m,1H),7.15(dd,J=1.5,6.5Hz,2H),7.32-7.36(m,2H),7.48(dd,J=1.5,6.5Hz,2H),7.48(s,1H),7.60-7.61(m,2H);13C NMR(125MHz,CDCl3)δ=12.26,12.72,104.50,114.54,119.75,123.57,128.85,128.92,129.44,129.68,134.58,134.98,136.01,138.51,163.89.
实施例2
用2-萘胺代替“实例1”中的4-氯苯胺,使用苯作溶剂,反应温度为50℃,其他条件同“实例1”,实验结果见表1。
谱图解析数据2b:
1H NMR(500MHz,CDCl3)δ=2.04(s,3H),2.39(s,3H),6.24(s,1H),7.07-7.97(m,13H);13CNMR(125MHz,CDCl3)δ=12.13,12.55,104.10,114.14,119.52,123.21,125.52,126.65,126.74,127.59,127.74,128.64,128.89,129.17,132.51,133.00,134.70,135.02,138.43,163.81;IR(KBr,cm-1)3257,3057,1638,1596,1577,1498,1309,1257,795,759,690;
实施例3
用苄胺代替“实例1”中的4-氯苯胺,同时,使用FeBr3,其他条件同“实例1”,实验结果见表1。
谱图解析数据2c:
1H NMR(500MHz,CDCl3)δ=2.15(s,3H),2.52(s,3H),5.05(s,2H),6.16(s,1H),6.90(d,J=8.0Hz,2H),7.06-7.34(m,5H),7.49(s,1H),7.59(d,J=8.0Hz,2H);13C NMR(125MHz,CDCl3)δ=11.17,12.21,46.68,61.49,104.32,113.96,119.72,123.39,125.45,127.36,128.20,128.84,128.85,134.54,136.90,138.63,164.09;IR(KBr,cm-1)3249,3027,1638,1536,1495,1435,1250,753,691;MS m/z Calcd:304.2;Found:305.2[(M+1)+].
实施例4
1)1b的制备步骤及条件同实施例1中1a;
2)用1b代替实例1中的4-戊炔酮1a,使用5mmol%的FeCl3作催化剂,其他条件同实例1,实验结果见表1。
谱图解析数据2d:
1H NMR(500MHz,CDCl3)δ=1.99(s,3H),2.33(s,3H),6.21(d,J=1.0Hz,1H),7.18(dd,J=2.0,6.5Hz,2H),7.43-7.51(m,5H),7.83(dd,J=1.0,8.0Hz,2H);13C NMR(125MHz,CDCl3)δ=12.61,12.95,110.07,119.72,127.91,128.22,128.98,129.32,129.69,131.01,137.63,135.89,137.11,140.66,192.27;IR(KBr,cm-1)3050,1631,1717,1493,1409,1251,1099,837,731,714,697;MS m/z Calcd:309.1;Found:310.1[(M+1)+].
实施例5
1)1c的制备步骤及条件同实施例1中1a;
2)用1c代替实例1中的2-乙酰基-N-苯基-4-炔戊酰胺1a,使用二氧六环作溶剂,其他条件同实例1,实验结果见表1。
谱图解析数据2e:
1H NMR(500MHz,CDCl3)δ=2.05(s,3H),2.06-2.11(m,3H),2.47-2.53(m,3H),6.38(s,1H),7.08-7.11(m,1H),7.15(dd,J=1.5,6.5Hz,2H),7.32-7.36(m,2H),7.48(dd,J=1.5,6.5Hz,2H),7.18(d,J=8.5Hz,1H),7.49(d,J=8.5Hz,1H);13C NMR(125MHz,CDCl3)δ=12.56,22.67,23.81,37.84,103.80,120.36,128.79,129.73,131.22,134.60,135.53,144.26,194.29;IR(KBr,cm-1)3279,1653,1494,1468,1091,795,505.
实施例6
1)1d的制备步骤及条件同实施例1中1a;
2)用1d代替实例1中的2-乙酰基-N-苯基-4-炔戊酰胺1a,使用乙腈作溶剂,其他条件同实例1,实验结果见表1。
谱图解析数据2f:
1H NMR(500MHz,CDCl3)δ=1.02(t,J=7.0Hz,3H),1.98(s,3H),2.32(s,3H),2.79(q,J=7.0Hz,2H),6.17(s,1H),7.13-7.19(m,4H),7.42(s,1H),7.50(m,4H);13C NMR(125MHz,CDCl3)δ=12.57,14.59,18.98,20.76,104.45,113.84,119.80,128.70,129.34,129.55,129.64,133.02,134.64,135.95,136.07,141.10,163.42;IR(KBr,cm-1)3278,1633,1596,1492,1268,1245,1089,854,736;MS m/z Calcd:352.1;Found:353.1[(M+1)+].
实施例7
1)1e的制备步骤及条件同实施例1中1a;
2)用1e代替实例1中的2-乙酰基-N-苯基-4-炔戊酰胺1a,其他条件同实例1,实验结果见表1。
谱图解析数据2g:
1H NMR(500MHz,CDCl3)δ=0.80(t,J=8.0Hz,3H),1.42(q,J=8.0Hz,2H),2.21(t,J=8.0Hz,2H),2.26(s,3H),6.12(s,1H),7.02(t,J=8.0Hz,1H),7.08(d,J=8.5Hz,2H),7.27(t,J=8.0Hz,2H),7.41(d,J=8.0Hz,2H),7.42(s,1H),7.54(d,J=8.0Hz,2H);13C NMR(125MHz,CDCl3)δ=12.13,13.79,21.90,28.69,103.57,114.55,119.78,123.57,128.92,129.62,129.66,133.80,134.62,134.89,136.04,138.54,163.96;IR(KBr,cm-1)3293,1630,1526,1494,1259,1091,1019,799,688.
实施例8
1)1f的制备步骤及条件同实施例1中1a;
2)用1f代替实例1中的2-乙酰基-N-苯基-4-炔戊酰胺1a,其他条件同实例1,实验结果见表1。
谱图解析数据2h:
1H NMR(500MHz,CDCl3)δ=2.06(s,3H),2.11(s,3H),3.83(s,3H),6.10(s,1H),6.93(d,J=7.0Hz,2H),7.21(dd,J=2.0,7.0Hz,2H),7.35(dd,J=2.0,7.0Hz,2H),7.45(dd,J=2.0,7.0Hz,2H);13C NMR(125MHz,CDCl3)δ=12.09,12.82,55.24,106.85,113.76,120.99,124.41,128.36,128.86,129.36,129.61,133.60,137.36,157.40;IR(KBr,cm-1)3727,2167,1494,1243,1090,1042,834,797,673.
表1
Claims (1)
1.吡咯衍生物2a的制备方法,其特征在于:
(1)4-戊炔酮化合物1a的制备
向带有磁力搅拌装置的50mL圆底烧瓶中加入无水N,N-二甲基甲酰胺15mL、N-乙酰乙酰苯胺1.77g和无水碳酸钾1.66g,在室温20℃、搅拌状态下,缓慢滴加3-溴丙炔1.43g,滴加速率以1滴/2秒为宜,持续搅拌12小时,得淡黄色反应液,将反应液倾入20mL饱和氯化钠水溶液中,用二氯甲烷3×15mL萃取,合并有机相,然后用水3×10mL反洗有机相,经过无水氯化钙干燥、抽滤、减压蒸馏,得到粘稠的固体,经过硅胶柱层析,洗脱液为V石油醚∶V乙酸乙酯=10∶3,得到白色固体1.25g,产物的结构经过NMR、MS证实为4-戊炔酮化合物1a,收率为58%;
(2)吡咯衍生物2a的制备
向带有磁力搅拌装置的25mL圆底烧瓶中加入二甲苯2mL、4-戊炔酮化合物1a 0.22g、4-氯苯胺0.13g和无水三氯化铁0.016g,搅拌均匀后,将其放入80℃油浴中继续搅拌,TLC检测底物消失,反应结束,将反应液倾入5mL饱和氯化钠水溶液中,用二氯甲烷3×5mL萃取,合并有机相,无水氯化钙干燥、抽滤,然后减压蒸馏除去有机溶剂,得到固体混合物,最后经过硅胶柱层析,洗脱液为V石油醚∶V乙酸乙酯=10∶3,得到淡黄色固体0.27g,经过NMR、MS证实为吡咯衍生物2a,其收率以2-乙酰基-N-苯基-4-炔戊酰胺为基础为83%。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010130160XA CN101798279B (zh) | 2010-03-23 | 2010-03-23 | 铁催化的吡咯及吡咯并环类化合物的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010130160XA CN101798279B (zh) | 2010-03-23 | 2010-03-23 | 铁催化的吡咯及吡咯并环类化合物的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101798279A CN101798279A (zh) | 2010-08-11 |
CN101798279B true CN101798279B (zh) | 2011-08-31 |
Family
ID=42594143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010130160XA Expired - Fee Related CN101798279B (zh) | 2010-03-23 | 2010-03-23 | 铁催化的吡咯及吡咯并环类化合物的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101798279B (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103145600B (zh) * | 2013-03-06 | 2015-06-03 | 东北师范大学 | 一种银催化的多取代吡咯类化合物的合成方法 |
CN103274993A (zh) * | 2013-06-13 | 2013-09-04 | 南京工业大学 | 二氢吡啶和吡咯类杂环的新合成方法 |
CN104860864B (zh) * | 2015-06-04 | 2017-09-15 | 广西师范大学 | 2‑羰基‑5‑炔基吡咯化合物的合成方法 |
CN105061286B (zh) * | 2015-09-08 | 2017-11-24 | 上海蓝木化工有限公司 | 一种炔基取代吡咯类化合物的合成方法 |
CN105949161B (zh) * | 2016-06-28 | 2018-05-15 | 温州大学 | 一种3-芳巯基黄酮化合物的制备方法 |
CN110105282A (zh) * | 2019-05-22 | 2019-08-09 | 南华大学 | 一种单取代吡唑类化合物的制备方法 |
CN110746335B (zh) * | 2019-10-21 | 2021-03-19 | 南京师范大学 | 一种多取代吡咯类化合物及其合成方法 |
CN110845386A (zh) * | 2019-12-03 | 2020-02-28 | 吉林工程技术师范学院 | 一种铁催化合成吡咯的方法、吡咯及应用 |
CN113173570B (zh) * | 2021-04-21 | 2022-12-09 | 国网黑龙江省电力有限公司电力科学研究院 | 一种类石墨烯片状氮掺杂多孔碳材料的制备方法及应用 |
-
2010
- 2010-03-23 CN CN201010130160XA patent/CN101798279B/zh not_active Expired - Fee Related
Non-Patent Citations (3)
Title |
---|
Antonio Arcadi,et al..Conversion of homochiral amines and α-amino esters to their chiral 1,2,3,5-substituted pyrrole derivatives via gold-catalysed amination/annulation reactions of 2-propynyl-1,3-dicarbonyl compounds.《Tetrahedron: Asymmetry》.2001,第12卷2715–2720. * |
AntonioArcadi et al..Conversion of homochiral amines and α-amino esters to their chiral 1 |
Yoshiaki Nishibayashi,et al..Novel Ruthenium- and Platinum-Catalyzed Sequential Reactions: Synthesis of Tri- and Tetrasubstituted Furans and Pyrroles from Propargylic Alcohols and Ketones.《Angew. Chem. Int. Ed.》.2003,第42卷2681-2684. * |
Also Published As
Publication number | Publication date |
---|---|
CN101798279A (zh) | 2010-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101798279B (zh) | 铁催化的吡咯及吡咯并环类化合物的制备方法 | |
CN107973778B (zh) | 一种钌催化芳香酮与二苯乙炔环化反应制备多芳取代萘衍生物的方法及应用 | |
CN107868036B (zh) | 一种多取代苯并[c,d]吲哚类化合物的合成方法 | |
CN111978236A (zh) | 一种n-取代-3-吗啉基-4-苯硒基马来酰亚胺化合物的制备方法 | |
CN108640917B (zh) | 一种吲哚并[2,1-a]异喹啉类化合物的合成方法 | |
CN103145600B (zh) | 一种银催化的多取代吡咯类化合物的合成方法 | |
Monguchi et al. | Synthesis of triazole, indole, and five or six-membered saturated heterocyclic compounds | |
CN112028809A (zh) | 一种3-胺基-4-苯硒基马来酰亚胺化合物的制备方法 | |
CN103664821B (zh) | 一种基于邻氨基苯硫酚环化的苯并噻唑类化合物制备方法 | |
CN106946682B (zh) | 一种丙炔酸类化合物的制备方法 | |
CN110041235A (zh) | 一种n-苯基-n-对甲苯磺酰基三氟乙酰胺及应用 | |
CN111978237B (zh) | 一种3-吗啉基-4-芳硒基马来酰亚胺化合物的制备方法 | |
CN102659658A (zh) | 一种高度官能化的吡咯类化合物的合成方法 | |
CN108084082A (zh) | 合成[b]-环化吲哚类衍生物的方法 | |
CN104817484B (zh) | 一种2‑吲哚酮衍生物及其制备方法 | |
CN109384705A (zh) | 一种金催化的苯并[a]咔唑的合成方法 | |
CN107629049B (zh) | 一种吡啶[2,1-a]并异吲哚类化合物的合成方法 | |
CN111484436A (zh) | 一种在吲哚c3位引入异戊烯基的方法 | |
CN106278989B (zh) | 3-氰基吲哚类化合物的合成方法 | |
CN109776546B (zh) | 一种制备吲哚并吡咯酮化合物的方法 | |
CN104193667B (zh) | 一种发散型导向的氮杂环的合成方法 | |
CN102516162A (zh) | 铜催化的硝基芳(杂)环化合物的制备方法 | |
CN113087667A (zh) | 一种咪唑啉酮衍生物的合成方法 | |
CN107459484B (zh) | 一种铜催化的有机发光二极管材料单元胺化反应的新方法 | |
CN107216331A (zh) | 一种四氢萘啶并四氢喹唑啉衍生物及其合成方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110831 Termination date: 20120323 |